VIR - Company ID 0001706431
The table below shows Vir Biotechnology, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | -$29.00K | $240.00K | $1.21M | $3.03M | $2.38M | $3.08M |
| Cost of revenue | - | - | $11.00K | $0.00 | $50.00K | $52.00K |
| Gross profit | - | - | - | - | - | - |
| R&D | $108.92M | $151.46M | $97.51M | $118.64M | $195.18M | $105.11M |
Vir Biotechnology, Inc. reported annual revenue of $68.56M for fiscal year 2025. That is down 7.6% from $74.20M in fiscal 2024. Over the 9 fiscal years shown, annual revenue grew from $2.71M (FY 2017) to $68.56M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $23.34M |
| $22.23M |
| $22.28M |
| $23.94M |
| $25.74M |
| $30.27M |
| Operating income | -$132.29M | -$173.44M | -$118.42M | -$139.55M | -$231.30M | -$158.63M |
| Income tax | $170.00K | $168.00K | $170.00K | $16.00K | $177.00K | -$1.51M |
| Net income | -$125.69M | -$163.14M | -$110.96M | -$120.97M | -$213.72M | -$138.38M |
| EPS (diluted) | -$0.85 | -$1.17 | -$0.80 | -$0.88 | -$1.56 | -$1.02 |